Table 1.
Characteristic | Categories | Psilocybin first |
Niacin first |
Total |
|||
---|---|---|---|---|---|---|---|
n=14 | n=15 | n=29 | |||||
Sex | Female | 7 | 50% | 11 | 73% | 18 | 62% |
Male | 7 | 50% | 4 | 27% | 11 | 38% | |
Age; mean (SD) | Range 22–75 | 52 (15.03) | 60.27 (9.45) | 56.28 (12.93) | |||
Race | White/Caucasian | 13 | 93% | 13 | 87% | 26 | 90% |
Black/African American | 0 | 0% | 0 | 0% | 0 | 0% | |
Hispanic/Latino | 0 | 0% | 0 | 0% | 0 | 0% | |
Asian | 0 | 0% | 0 | 0% | 0 | 0% | |
American Indian/Native American | 0 | 0% | 0 | 0% | 0 | 0% | |
Other | 1 | 7% | 2 | 13% | 3 | 10% | |
Religious/spiritual beliefs | Atheist/agnostic | 4 | 29% | 10 | 67% | 14 | 48% |
Jewish | 4 | 29% | 1 | 7% | 5 | 17% | |
Catholic | 2 | 14% | 0 | 0% | 2 | 7% | |
Other Christian | 3 | 21% | 1 | 7% | 4 | 14% | |
Other faith/tradition | 1 | 7% | 3 | 20% | 4 | 14% | |
Site of cancer | Breast | 4 | 29% | 5 | 33% | 9 | 31% |
Reproductive | 3 | 21% | 5 | 33% | 8 | 28% | |
Digestive cancers | 3 | 21% | 2 | 13% | 5 | 17% | |
Lymphoma/leukemia | 2 | 14% | 2 | 13% | 4 | 14% | |
Other types | 2 | 14% | 1 | 7% | 3 | 10% | |
Stage of cancer | Stage IV | 3 | 21% | 7 | 47% | 10 | 34% |
Stage III | 4 | 29% | 4 | 27% | 8 | 28% | |
Stage II | 1 | 7% | 4 | 27% | 5 | 17% | |
Stage I | 5 | 36% | 0 | 0% | 5 | 17% | |
Other | 1 | 7% | 0 | 0% | 1 | 3% | |
SCID (DSM-IV) diagnosisb | Adjustment disorder w/anxiety and depressed mood, chronic | 2 | 14% | 6 | 40% | 8 | 28% |
Adjustment disorder w/anxiety, chronic | 10 | 71% | 8 | 53% | 18 | 62% | |
Generalized anxiety disorder | 2 | 14% | 1 | 7% | 3 | 10% | |
Hallucinogen use | No | 7 | 50% | 6 | 40% | 13 | 45% |
Yes | 7 | 50% | 9 | 60% | 16 | 55% | |
Employment status | Full-time employed | 6 | 43% | 5 | 33% | 12 | 41% |
Part-time employed | 2 | 14% | 2 | 13% | 4 | 14% | |
Full-time student | 1 | 7% | 0 | 0% | 1 | 3% | |
Unemployed | 2 | 14% | 1 | 7% | 2 | 7% | |
Self-employed | 1 | 7% | 1 | 7% | 2 | 7% | |
Retired | 0 | 0% | 6 | 40% | 6 | 21% | |
Long-term disability | 2 | 14% | 0 | 0% | 2 | 7% | |
Educational attainment | Grade 7–12 w/o graduating high school | 1 | 7% | 0 | 0% | 1 | 3% |
Graduated HS or equivalent | 0 | 0% | 1 | 7% | 1 | 3% | |
Part college | 1 | 7% | 3 | 20% | 4 | 14% | |
Graduated 4-year college | 5 | 36% | 4 | 27% | 9 | 31% | |
Completed grad/professional school | 7 | 50% | 7 | 47% | 14 | 48% | |
Marital status | Never married | 5 | 36% | 3 | 20% | 8 | 28% |
Widowed | 0 | 0% | 2 | 13% | 2 | 7% | |
Cohabitation | 2 | 14% | 0 | 0% | 2 | 7% | |
Divorced | 1 | 7% | 3 | 20% | 4 | 14% | |
Married | 6 | 43% | 7 | 47% | 13 | 45% | |
Living arrangements | Live with spouse/partner/family | 11 | 79% | 9 | 60% | 20 | 69% |
Live alone | 2 | 14% | 6 | 40% | 8 | 28% | |
Other; lived with roommates | 1 | 7% | 0 | 0% | 1 | 3% |
The two dose-sequence groups did not significantly differ on any demographic or clinical characteristic measures.
Psychiatric classification was based on the structured clinical interview for the DSM-IV (SCID-IV).
Nearly two-thirds (59%) of participants had previously been treated with anti-depressant or anxiolytic medication, but none were on any psychotropics before study enrollment per inclusion/exclusion criteria.